Amtagvi monotherapy achieved a 25.6% objective response rate and 71.8% disease control rate in NSCLC patients without actionable mutations. The median duration of response was not reached after 25.4 ...

Please provide your email address to receive an email when new articles are posted on . Guidelines for the management of early-stage non-small cell lung cancer were last published in 2013. The new ...

Sunvozertinib is the first targeted oral treatment for NSCLC with EGFR exon 20 insertion mutations, approved for post-chemotherapy progression cases. The WU-KONG1 Part B study showed a 53.3% objective ...

Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non-small cell lung cancer. Data are n (%). This is an ASCO Meeting ...

Findings from a study led by researchers at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James) support the ...

Dr Jonathan Goldman of the University of California, Los Angeles, highlights key abstracts in early-stage NSCLC from ASCO 2025. Dr Goldman begins with updated results from CheckMate 816, comparing ...

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small-cell lung cancer will benefit from immunotherapy.

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...

You and your family are our top priority. At Fred Hutch Cancer Center, we offer comprehensive and compassionate care — personalized to you. You'll have access to the latest treatment options, clinical ...